|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.28 CNY | -2.04% |
|
+1.53% | -25.10% |
| 12-02 | Yiling Pharmaceutical Unit Gets Nod to Market Simvastatin Tablets in US | MT |
| 11-29 | Shijiazhuang Yiling Pharmaceutical's Tongluo Mingmu Capsules Added to National Medical Insurance Catalog | MT |
| Capitalization | 28.87B 3.97B 3.78B 3.54B 3.14B 5.65B 337B 6.24B 43.59B 16.12B 139B 14.91B 14.58B 610B | P/E ratio 2024 * |
21.4x | P/E ratio 2025 * | 17.9x |
|---|---|---|---|---|---|
| Enterprise value | 28.26B 3.88B 3.7B 3.47B 3.08B 5.53B 329B 6.11B 42.67B 15.78B 136B 14.59B 14.27B 597B | EV / Sales 2024 * |
2.69x | EV / Sales 2025 * | 2.29x |
| Free-Float |
42.61% | Yield 2024 * |
1.19% | Yield 2025 * | 1.48% |
More valuation ratios
* Estimated data
More news
More news
| 1 day | -2.04% | ||
| 1 week | +1.53% | ||
| Current month | +0.35% | ||
| 1 month | -5.68% | ||
| 3 months | +17.31% | ||
| 6 months | +0.23% | ||
| Current year | -25.10% |
1 week
16.83
17.91
1 month
16.6017.91
Current year
14.3724.47
1 year
14.3724.57
3 years
14.3753.96
5 years
7.8653.96
10 years
7.0853.96
| Director | Title | Age | Since |
|---|---|---|---|
Xiang Jun Wu
CEO | Chief Executive Officer | 49 | 2013-03-31 |
Chen Guang Li
DFI | Director of Finance/CFO | 51 | 2018-04-23 |
Qiu Lian Zhang
PRN | Corporate Officer/Principal | 54 | 2020-01-15 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yi Ling Wu
CHM | Chairman | 75 | 2012-08-30 |
Xiang Jun Wu
BRD | Director/Board Member | 49 | 2010-08-30 |
Chen Guang Li
BRD | Director/Board Member | 51 | 2018-05-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.90% | 1 M€ | -20.08% | - | |
| 0.66% | 4 M€ | -2.96% | ||
| 0.57% | 2 M€ | -14.14% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -2.04% | +1.53% | -31.62% | +4.60% | 3.97B | ||
| -0.88% | +4.24% | +17.78% | +32.46% | 5.29B | ||
| -1.26% | +2.27% | -14.14% | +7.05% | 3.06B | ||
| -1.80% | +0.75% | -9.86% | +22.70% | 2.95B | ||
| -1.74% | -0.82% | -5.25% | -8.96% | 2.48B | ||
| -2.56% | -0.95% | -8.52% | -1.64% | 1.73B | ||
| -2.56% | -2.61% | +24.04% | +68.11% | 1.68B | ||
| -2.96% | -0.98% | -6.06% | -17.46% | 1.63B | ||
| -2.00% | -1.25% | +50.68% | +106.83% | 1.57B | ||
| -3.71% | -1.82% | -36.19% | -44.21% | 1.31B | ||
| Average | -2.15% | +1.06% | -1.91% | +16.95% | 2.57B | |
| Weighted average by Cap. | -1.86% | +1.77% | -2.68% | +17.51% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 10.49B 1.44B 1.37B 1.29B 1.14B 2.05B 122B 2.27B 15.84B 5.86B 50.4B 5.42B 5.3B 222B | 11.88B 1.63B 1.56B 1.46B 1.29B 2.33B 139B 2.57B 17.94B 6.64B 57.08B 6.14B 6B 251B |
| Net income | 1.35B 186M 177M 166M 147M 264M 15.75B 292M 2.04B 754M 6.49B 698M 682M 28.53B | 1.61B 221M 211M 198M 175M 315M 18.76B 348M 2.43B 899M 7.73B 831M 813M 33.99B |
| Net Debt | -610M -83.87M -79.9M -74.92M -66.44M -119M -7.11B -132M -921M -341M -2.93B -315M -308M -12.89B | -1.65B -227M -217M -203M -180M -324M -19.29B -358M -2.5B -924M -7.95B -855M -835M -34.95B |
More financial data
* Estimated data
Employees
13,958
Sector
Pharmaceuticals
Calendar
2025-04-23
- Q1 2025 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-13 | 17.28 ¥ | -2.04% | 61,040,000 |
| 24-12-12 | 17.64 ¥ | +3.58% | 48,974,730 |
| 24-12-11 | 17.03 ¥ | +0.71% | 12,310,050 |
| 24-12-10 | 16.91 ¥ | -0.18% | 18,021,920 |
| 24-12-09 | 16.94 ¥ | -0.47% | 14,068,380 |
End-of-day quote Shenzhen S.E., December 12, 2024
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.28CNY
Average target price
20.95CNY
Spread / Average Target
+21.22%
Annual profits - Rate of surprise
- Stock Market
- Equities
- 002603 Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition